#United States #Coeur d'Alene #Oncology Conference #Summit Cancer #Dr. Arvind Chaudhry

Summit Cancer Center's Dr. Arvind Chaudhry to Lead Coeur d'Alene Oncology Conference

In an exciting development for oncology education and collaboration, Dr. Arvind Chaudhry, Founder and Medical Director of Summit Cancer Centers, will chair the Coeur d'Alene Hematology Oncology Conference set to take place on October 11, 2025, at the picturesque Coeur d'Alene Resort in Idaho. This vital continuing medical education (CME) event aims to enhance understanding of precision-guided cancer care and will offer attendees 6.0 CME credits, MOC II points, and ACPE credits.

The Coeur d'Alene conference is part of the esteemed Binaytara CME Conference Series, established in collaboration with Dr. Binay Shah, who is the president and co-founder of the Binaytara Foundation. Beginning in 2015 as a modest gathering discussing highlights from major oncology events like ASCO and ASH, this conference has progressively evolved into a key annual event attracting oncology professionals nationwide.

Dr. Chaudhry emphasizes the conference's goal: “Our aim is to foster healthy discussions rather than merely delivering lectures. We invite all cancer-treating physicians—including medical oncologists, radiation oncologists, and surgical oncologists—into a collaborative format that resembles a tumor board.”

Among the highlights of the upcoming conference is a session dedicated to lung cancer, an area of considerable importance due to ongoing advancements in therapy. As Dr. Chaudhry notes, “The landscape for lung cancer treatment is very dynamic, especially with a surge in FDA approvals for targeted treatments and immunotherapies. It's both exciting and imperative to share this knowledge.” He underscores that treatments once employed in advanced stages are now being applied in earlier contexts, both pre- and post-surgery.

Beyond educational initiatives, Dr. Chaudhry's impact extends to clinical research within community settings. Recently, he participated in the Artistry-1 trial, which explored a novel immunotherapy designed for melanoma and renal cell carcinoma. This groundbreaking study highlights the importance of expanding access to early-phase trials in local communities, suggesting safer alternatives compared to older treatments like IL-2.

With a commitment to bridging gaps between research, education, and patient care, Dr. Chaudhry states, “Summit Cancer Centers strives to close the divide between discovery and delivery. By merging clinical research with education, we expedite access to new therapies for patients, enhancing their treatment options.”

The Coeur d'Alene conference exemplifies this mission, uniting community oncologists with leading specialists from prominent institutions, including Seattle, Portland, and Stanford. The format encourages practical and case-based discussions aimed at improving clinical outcomes across the region.

Interested individuals can find more details about this vital educational opportunity at binaytara.org/conferences. To learn more about Summit Cancer Centers and its impactful work, visit summitcancercenters.com.

For media inquiries, please contact John Driscoll at Summit Cancer Centers at 509-462-2273 or via email at [email protected].